Braxia Scientific (XCNQ:BRAX) Gross-Profit-to-Asset % : 12.50% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Braxia Scientific Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Braxia Scientific's annualized Gross Profit for the quarter that ended in Dec. 2023 was C$0.33 Mil. Braxia Scientific's average Total Assets over the quarter that ended in Dec. 2023 was C$2.63 Mil. Therefore, Braxia Scientific's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 12.50%.

Braxia Scientific Gross-Profit-to-Asset % Historical Data

The historical data trend for Braxia Scientific's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Braxia Scientific Gross-Profit-to-Asset % Chart

Braxia Scientific Annual Data

Trend

Mar21

Mar22

Mar23

Gross-Profit-to-Asset %

0.79

1.64

2.22

Braxia Scientific Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial												0.35	1.51	10.68	18.37	12.50

Competitive Comparison of Braxia Scientific's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Braxia Scientific's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Braxia Scientific's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Braxia Scientific's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Braxia Scientific's Gross-Profit-to-Asset % falls into.

Braxia Scientific Gross-Profit-to-Asset % Calculation

Braxia Scientific's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Mar. 2023 )	/	( (Total Assets (A: Mar. 2022 )	+	Total Assets (A: Mar. 2023 ))	/ count )
	=	0.172	/	( (11.634	+	3.884)	/ 2 )
	=	0.172	/	7.759
	=	2.22 %

Braxia Scientific's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0.328	/	( (2.912	+	2.338)	/ 2 )
	=	0.328	/	2.625
	=	12.50 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Braxia Scientific Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Braxia Scientific's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Braxia Scientific (XCNQ:BRAX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Braxia Scientific Corp (XCNQ:BRAX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

BRAXF:USA 4960:Germany

Address

700 Bay Street, Suite 1903, Toronto, ON, CAN, M5G 1Z6

Website

https://www.braxiascientific.com

Braxia Scientific Corp is a research-driven medical solutions company that aims to reduce the illness burden of brain-based mental disorders such as depressive disorder among others. It is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing novel drugs and delivery methods. The company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.

Braxia Scientific (XCNQ:BRAX) Headlines

No Headlines